<SEC-DOCUMENT>0001564590-22-024885.txt : 20220630
<SEC-HEADER>0001564590-22-024885.hdr.sgml : 20220630
<ACCEPTANCE-DATETIME>20220630084016
ACCESSION NUMBER:		0001564590-22-024885
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220627
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220630
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		221056608

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hrtx-8k_20220627.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-06-30T04:21:36.1319027+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : 35c4c7a91e8947ab8c23cc21f50a1bec -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hrtx="http://www.herontx.com/20220627" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
hrtx-8k_20220627.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000818033_20220627_20220627">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000818033_20220627_20220627">0000818033</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="hrtx-20220627.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000818033_20220627_20220627">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-06-27</xbrli:startDate>
					<xbrli:endDate>2022-06-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000818033_20220627_20220627">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000818033_20220627_20220627" format="ixt:datemonthdayyearen">June 27, 2022</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000818033_20220627_20220627">Heron Therapeutics, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000818033_20220627_20220627">001-33221</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000818033_20220627_20220627">94-2875566</ix:nonNumeric></p></td>
</tr>
<tr style="height:21.15pt;">
<td valign="top" style="width:30.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:29.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000818033_20220627_20220627">4242 Campus Point Court</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0000818033_20220627_20220627">Suite 200</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0000818033_20220627_20220627">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0000818033_20220627_20220627">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0000818033_20220627_20220627">92121</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:56.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0000818033_20220627_20220627">(858)</ix:nonNumeric> <ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0000818033_20220627_20220627">251-4400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:38.25%;margin-right:38.22%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Emoji;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39.92%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:22.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:34.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:39.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0000818033_20220627_20220627">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0000818033_20220627_20220627">HRTX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:34.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Emoji;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000818033_20220627_20220627" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Emoji;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt #000000;padding-bottom:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.05 Costs Associated with Exit or Disposal Activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 27, 2022, the Board of Directors of Heron Therapeutics, Inc. (the &#8220;Company&#8221;) approved a reduction in force that is expected to result in the termination of approximately 34% of the Company&#8217;s workforce. The reduction in force is being implemented in order to enable the Company to decrease its costs and maintain a streamlined organization to support its acute care and oncology care franchises. The reduction in force is a component of the Company&#8217;s broader efforts to address the current market dynamics and prepare the Company for long-term sustainability. The employees impacted by the reduction in force will exit the Company in the third and fourth quarters of 2022. The Company will provide employees with one-time severance payments upon termination, continued benefits for a specific period of time, outplacement services and certain equity award modifications. The Company expects to incur total expenses of $6.3 million, $5.9 million of which is primarily for severance and related costs and $0.4 million of which is for non-cash, stock-based compensation expense related to equity award modifications. The Company anticipates recognizing $4.3 million of the total expenses in the second quarter of 2022, $1.3 million of the total expenses in the third quarter of 2022 and $0.7 million of the total expenses in the fourth quarter of 2022. The Company expects the cash payments due to terminated employees will be substantially completed in the first quarter of 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2022, the Company issued a press release regarding its restructuring and cost reduction plan, a copy of which is furnished herewith as Exhibit 99.1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hrtx-ex991_6.htm"><span style="text-decoration:underline;">Press Release, dated June 30, 2022</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <span style="color:#000000;">June 30, 2022</span></p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Szekeres</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hrtx-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hrtx-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2cxwlzv1ywa000001.jpg" title="" alt="" style="width:152px;height:59px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31720604"></a><a name="_Hlk480203125"></a>Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-right:6.69%;text-indent:5.82%;font-size:11pt;font-family:Arial;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;">- Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend <font style="font-style:normal;">-</font> </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-right:6.69%;text-indent:5.82%;font-size:11pt;font-family:Arial;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;">- Reduces organization headcount by 34% - </p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-right:6.69%;text-indent:5.82%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-right:6.69%;text-indent:5.82%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">- Priorities remain on commercial growth for both the Acute Care and Oncology Care franchises -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-right:6.69%;text-indent:5.82%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO, June 30, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a corporate restructuring and cost reduction plan to address the current market dynamics and prepare the company for long-term sustainability. The Company expects these actions will result in annualized cost savings of $43 million and will enable Heron to maintain a streamlined organization to support its acute care and oncology care franchises and extend its cash runway.</p>
<p style="Background-color:#FFFFFF;margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#8220;To address the current market realities and the macro headwinds facing many commercial-</font><font style="color:#000000;">stage biotechnology companies, we are enacting critical plans to protect Heron&#8217;s long-term sustainability and growth plans. This restructuring and cost reduction plan is expected to support our operations, with ongoing business development activities intended to provide the resources to further extend the runway,&#8221; said&#160;Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. &#8220;We continue to have tremendous confidence in ZYNRELEF</font><font style="font-style:italic;font-size:10pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="color:#000000;"> and our oncology care franchise products, CINVANTI</font><font style="font-style:italic;font-size:10pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="color:#000000;"> and SUSTOL</font><font style="font-style:italic;font-size:10pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="color:#000000;">, with increased sales across both franchises in the second quarter compared to the first quarter of this year. Our commercial team is continuing to focus on accelerating the usage of ZYNRELEF and growing demand unit sales of our oncology care products. Our research and development team is continuing to focus on the label expansion for ZYNRELEF in the U.S. and continuing to work towards approval of HTX-019 for postoperative nausea and vomiting (PONV) with the U.S. Food and Drug Administration (FDA).&#8221;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s restructuring and cost reduction plan includes the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.88%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.88%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Arial;color:#000000;">Workforce reduction</font><font style="font-family:Arial;color:#000000;">: The majority of the cost savings will result from a significant workforce reduction across the Company&#8217;s research and development organization, with approximately 70% of the total employee reductions coming from research and development. The remaining research and development team will support the label expansion for ZYNRELEF, and the HTX-019 new drug application for PONV. In total, these actions will result in a reduction of the total company employee base by 34%. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.88%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.88%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Arial;color:#000000;">Streamlined operational expenditures</font><font style="font-family:Arial;color:#000000;">: Includes reductions and reallocations in overall sales, general and administrative (SG&amp;A) expenses, as well as savings related to reduced external spend.</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2cxwlzv1ywa000001.jpg" title="" alt="" style="width:152px;height:59px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Quart continued, &#8220;These restructuring and cost reduction actions, while difficult, are necessary to address the challenging operating landscape and better position Heron to improve the lives of patients while creating long-term value for shareholders. On behalf of the Board of Directors, I would like to recognize our valued colleagues who are departing Heron. We are extremely grateful for their contributions and dedication that have enabled us to deliver three important drugs in the last five years that help patients, with another expected soon. These accomplishments are truly remarkable, and we look forward to continuing to execute on our multi-franchise strategy with the team in place.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About ZYNRELEF<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for Postoperative Pain</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids&#160;through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in&#160;May 2021&#160;for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF&#8217;s indication. ZYNRELEF is now indicated in the U.S. in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. In&#160;September 2020, the&#160;European Commission&#160;granted a marketing authorization for ZYNRELEF for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.&#160;As of&#160;January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the&#160;European Union&#160;and European Economic Area and the&#160;United Kingdom. In March 2022, Health Canada issued a Notice of Compliance for ZYNRELEF for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see full prescribing information, including Boxed Warning, at&#160;<font style="text-decoration:underline;">www.ZYNRELEF.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About HTX-019&#160;for PONV</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HTX-019 is an IV injectable emulsion formulation designed to directly deliver aprepitant, the active ingredient in EMEND&#174;&#160;(aprepitant) capsules, which is the only substance P/neurokinin-1 (NK1) receptor antagonist (RA) to be approved in&#160;the U.S.&#160;for the prevention of PONV in adults. The&#160;FDA-approved dose of oral EMEND is 40 mg for PONV prevention, which is given within 3 hours prior to induction of anesthesia&#160;for surgery. In a Phase 1 clinical trial, 32 mg of HTX-019 as a 30-second IV injection was demonstrated to be bioequivalent to oral aprepitant 40 mg. The new drug application (NDA) for HTX-019 for PONV was submitted in November 2021 and the FDA set a PDUFA goal date of September 17, 2022.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2cxwlzv1ywa000001.jpg" title="" alt="" style="width:152px;height:59px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND&#174;&#160;capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1&#160;RA to significantly reduce nausea and vomiting in both the acute phase (0&#8211;24 hours after chemotherapy) and the delayed phase (24&#8211;120 hours after chemotherapy). The&#160;FDA-approved dosing administration included in&#160;the U.S.&#160;prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see full prescribing information at&#160;<font style="color:#1D4095;text-decoration:underline;">www.CINVANTI.com</font><font style="color:#1E1E1E;">.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:12pt;text-indent:0%;font-weight:bold;color:#1E1E1E;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About SUSTOL for CINV Prevention</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron&#8217;s Biochronomer<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;drug delivery technology to maintain therapeutic levels of granisetron for &#8805;5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#8217;s efficacy and safety in more than 2,000 patients with cancer. SUSTOL&#8217;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0&#8211;24 hours after chemotherapy) and delayed phase (24&#8211;120 hours after chemotherapy).<br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see full prescribing information at&#160;<font style="color:#1D4095;text-decoration:underline;">www.SUSTOL.com</font><font style="color:#1E1E1E;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Heron Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.&#160;is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach&#160;to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit&#160;<font style="text-decoration:underline;">www.herontx.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2cxwlzv1ywa000001.jpg" title="" alt="" style="width:152px;height:59px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including, but not limited to, </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing and results of studies for the further expansion of the U.S. label for ZYNRELEF; the potential market opportunities for ZYNRELEF in the U.S., Europe and Canada; the timing of the NDA review process for HTX-019 and whether the FDA approves HTX-019; the </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022 second quarter </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net product sales for the oncology care franchise; </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the 2022 second quarter net product sales for ZYNRELEF; </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the expected future balances of Heron&#8217;s cash, cash equivalents and short-term investments; the expected duration over which Heron&#8217;s cash, cash equivalents and short-term investments balances will fund its operations;</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the extent of the impact of the ongoing Coronavirus Disease 2019 pandemic on our business; and other risks and uncertainties identified in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations and Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Szekeres</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Chief Operating Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Heron Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dszekeres@herontx.com </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">858-251-4447</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2cxwlzv1ywa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2cxwlzv1ywa000001.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A /<# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           @)!PH$!08#"P(!_\0 5Q   00" @$ ! 8)
M#P<*!P  ! (#!08!!P ("1$2$Q05%ADA6-87(B,Q-W:6E]4*)#8X5E=9=WB4
ME;.TM=AA<71U@;:W&#(T.3I!0E&QPC6(D=37\/'_Q  = 0$  @(# 0$
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M.ID*H$NWCR8:ES<KTG/&5P]$:%;QM;@Q>1C$X3J18WKL?)LC,[7LV<TO<@I
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M1TV6-.RN2+T$BV3X>07+1,7*.1TC$+DH\(]<3,-,,2T8HP9LA4?*,#$%CLR
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M /VOI;^+]M_-M4[>6W8?CMV!5=+5OHJC4]G[B2NX:>/KXOJM%1 <FV"XHUG
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MTKZ^#Y>MMNG_ *_+&[DUK#UJH>E=5N@5CB9]#W)</F!YB.<EMLO.?L?6:O\
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M.B;WM0-MQF,TEK&0C[7L(V6RC/NH,V. 0['4<9U?JJ>/N!D5GW;UUQHDJ9[
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M,Y]@A]3]0L)]>(+PX/C#>&3'@%$LHSCUVVW$H7G*L9SS([<SRMQXXLBFNRL
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MW5G$*/)&9CT*93E(ZRDDO?<&7.9I&:SW>17]K-H5%IL.=:]^,=:\.$5VN$?
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hrtx-20220627.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-06-30T04:21:36.1319027+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : 35c4c7a91e8947ab8c23cc21f50a1bec -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:hrtx="http://www.herontx.com/20220627" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.herontx.com/20220627" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.herontx.com/20220627/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20220627_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20220627_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hrtx-20220627_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-06-30T04:21:36.1319027+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : 35c4c7a91e8947ab8c23cc21f50a1bec -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hrtx-20220627_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-06-30T04:21:36.1319027+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : 35c4c7a91e8947ab8c23cc21f50a1bec -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.herontx.com/20220627/role/TemplateLink" xlink:href="hrtx-20220627.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hrtx-20220627.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140325226123360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 27,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Heron Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-2875566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4242 Campus Point Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>hrtx-8k_20220627_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrtx-20220627.xsd" xlink:type="simple"/>
    <context id="C_0000818033_20220627_20220627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
        </entity>
        <period>
            <startDate>2022-06-27</startDate>
            <endDate>2022-06-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000818033_20220627_20220627" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000818033_20220627_20220627" id="F_000004">0000818033</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000818033_20220627_20220627" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000818033_20220627_20220627" id="F_000002">2022-06-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000818033_20220627_20220627" id="F_000003">Heron Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000818033_20220627_20220627" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000818033_20220627_20220627" id="F_000006">001-33221</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000818033_20220627_20220627" id="F_000008">94-2875566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000818033_20220627_20220627" id="F_000009">4242 Campus Point Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000818033_20220627_20220627" id="F_000010">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000818033_20220627_20220627" id="F_000011">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000818033_20220627_20220627" id="F_000012">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000818033_20220627_20220627" id="F_000013">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000818033_20220627_20220627" id="F_000014">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000818033_20220627_20220627" id="F_000015">251-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000818033_20220627_20220627" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000818033_20220627_20220627" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000818033_20220627_20220627" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000818033_20220627_20220627" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000818033_20220627_20220627" id="F_000020">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000818033_20220627_20220627" id="F_000021">HRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000818033_20220627_20220627" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000818033_20220627_20220627" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ !T7>5)>*NQS
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M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
M!T7>5"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ !T7>5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  '1=Y4^'(9
M;^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  '1=Y4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  =%WE0!M1OC< 0  $$1
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  '1=Y4GZ ;\+$"  #B#   #0              @ &S#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  =%WE27BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hrtx-8k_20220627.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="hrtx-8k_20220627.htm">hrtx-8k_20220627.htm</File>
    <File>hrtx-20220627.xsd</File>
    <File>hrtx-20220627_lab.xml</File>
    <File>hrtx-20220627_pre.xml</File>
    <File>hrtx-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hrtx-8k_20220627.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "hrtx-8k_20220627.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrtx-20220627_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrtx-20220627_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hrtx-20220627.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hrtx",
   "nsuri": "http://www.herontx.com/20220627",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20220627.htm",
      "contextRef": "C_0000818033_20220627_20220627",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hrtx-8k_20220627.htm",
      "contextRef": "C_0000818033_20220627_20220627",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "verboseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "verboseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com/20220627/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-22-024885-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-024885-xbrl.zip
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M7T107@)$.N?S.>>S9 /Y]'DY(^ )<8$9/6LXS58#(.JQ,:;3L\9"6%!X&#>
M\"$=0\(H.FNLD&A\/O_YIT^_6!:XO.[?@@O/QT_H$@N/,+'@Z,W@RUOP[?>'
M&W"#Z8\1% A<,F\Q0]0'%GCT_7G7MI^?GYOC"::"D84OV4738S,;6%8,W>,(
MJC^ 2^@C$/QT@=MR7:OUP6JWAJV3KNMTVQ^:3MOIM-S3WUJM;JNU ?!7>%A@
MXZ<+WC=;3:=Y>G*Z,? >>C_@%('^Y<; ]GOOQ#N%'0=][)R<PM%'SVU[GNM,
MWK>@,T+>9J5LON)X^NB#-][;H$1YO)0B0M *7&,*J8<A 8/X2-^!/O6:X((0
M\*"F"?" !.)/:-R,4(G4K4MB\:1'5 1/SQH;ZBU'G#09G]INJ]6VX]&-:/AR
M9_QS.QCM=#H=._CKRU"!TP9*6,?^]N5FX#VB&;2D53(%GB(0N"N"%V^8%WA4
MH"Z0.4(]L^)AEGK)<ERK[3278MR0:@ 0ZL$900]H M3OKP_]3,Z.K4;8%$UE
M<,8W<(2(K#F >.1HDCZ/<)Z8INKHJ#J<#ZJ.7]/0_-5<]H/ LSF1JMBU2[U%
MOMYJMP%U%WR/.&;C*ZI9Y'38PQ0_\"'7K'H6L.X#&,KS&]);^BZD]J*9#XGF
MHG<@-19=(1O^;IUU@S"!8A30R"5Y"N$\I"(*U(9++"[1!"Z(OUNFD).#&G<0
MU#)E(^(+]8J"$Y9Z*2@X!3*[YJ *M=!'(Q56SGH05AZN/AO(:.DC.D;1"?\%
MFWG9AR20UYRR)WN,<'@T\L'Z&.23[U?4Q_ZJ)_<=')*^A%_^B59)7J)6,,;C
M%X.#.6OD3+:3!:KQ:AF5C]26"5'KZZ HV'<RVLH$1X(M>+#&%M;27_?L>4@#
M(AX0$ ')],E>%[1;_P7W$E5 [L4%R(=[:HA&V!Z3>X.Y;Y'-I$\XF^6J&=&R
MO2K9.G/18W++>S$2DL;SB^9A:U*U'"1 ]/@?"GX>((-_8^S_CF]YNLHL4PBM
M%L<7'$-Y>$4=3LZI9O FAO[^?KF,4O#'=SA59)8EA"F"DE):UHOAA608*Y9K
M J=%<[@UJ9IN"1#]27R!!PK_^%%,%YIE:F&,J*2<GGK.BB]76.K>2MG3X];D
M>FV= -.CJ%Q81FSWE!DR 4D5W%$Z?F3SS6![=3).^.T3:V'%=>SR'] 4J]T$
M]6_AK'"FT^?6V>,GL0ZVQ5_3 ,5S_#3GNL#V*62:XJ2ZV,>]&DP67N)"4$</
M7LT0GV(Z_8.S9_^QQV9S2$M>;V= U,E'*N3!&C-F R$=B/A,:=!\BUA!W0RU
M@]1S0D<+7&.";A>S$>+E<K\YKXZZ:YR#)5Q1@)##E%2GJ,[R5#%)85)>7!U!
M[5./\3GCP?MW U_NSWIL(5>+58^-2VZ?]D#5$3L7^F )3["^ P$O8!Q$W$"1
MFQ+]8CZRDJ(:[AG)MBMRJYA5.AII")?]L=QGX0D.WPRO<OK/!*EC1 ;HP=I&
M\H$DH6'+Q#ZK6&'UC+6%U'5$1TM<C,>R=A']NL$4.>7:(16@CN8I@ =K@XCD
M7?Q ?0H*@3MJS)*19P\KI)J15I T%Q(F.*\=>[=N[%W=6KNO'/OA,S,W]F[1
MV+N'B+TF*_;'WGV5V/?DPSL^9,^T4N@WIVO0>0UW^, K+G5YH-@,"WN**6E1
MWU;+0 /28QY(?[=/>HTI#ZXN[O@]9T^8>B4OE+,P-,B]A7F(=]*V8_]R61R3
M&I;]+*O2&B!5/E-M26^%T(Z[(G9H[(=[)GQ(_L'S\K>-TA$TB)Y ?(U." F!
M9#3JUE"N16E=D"*<F7:D=T!A&VI^>E =&D>P3.*3<RI^=G #0_^F)EA)%;PA
M$4Y5F64I88JBI)R8]8*HOGU#[A\9+?F.T^Z\:O)MX^@/9<   @IC;B5FJL[R
M5#%)85)>W'I!_9MCWT>TQV:S!8UN1(JB:<V87$W05##]N8UH0)+G^-G--X+M
MU<@XT4DUO>O%>< (]K"/Z?2+W')S#$G1+*?-K*;I+I+^%*\Y0$QR_ CGB,_R
MI3%+:%)!XWJQO>=(]0>2\@8?J%??M^)WDTGQC4,>0C5ULQ'UQUER6=X&&0C9
M0$!W_& 7L(<5$\U,*\B+"Z!7W@6MT>\+L4"\?@.DX&C1?@?W%9HAY#2[)[)]
M2^^,#!U-]BBK2TK94W-[@[R%W$^M''<TQ#XI?(]C=U[%%7<+1W_X UC )L!Q
MWXS>@ICP^'G/E)[E26.2S/&V9@T. O1#A77(H?IG-8/5;,0*;\.W)E73+P%R
M@(R&\"#$/WXTTX5FF5H8(RHIIZ>><^?5TGN4!XK*?!<I?6Z]YM[$.L %8L0"
M8AI#OHN4ZP+;IY!IBI-28F^^<",?J7\G%;V$PW^Q=/X_4$L#!!0    (  =%
MWE1+CX.-%04  !HM   5    :')T>"TR,#(R,#8R-U]P<F4N>&ULY5IMC^(V
M$/Y>J?_!3;_<J<TKN\N"ECO1?3FA[IM8VI[ZY60< ]8Y-K(#"_^^X[ AL"2W
M<)N<N@H?>,O,^)G'D_&,X[./BXBC.56:2=&Q?,>S$!5$ADR,.]9,VU@3QBRD
M8RQ"S*6@'6M)M?7QP\\_G?UBV^CBJG>+NB1F<WK!-.%2SQ1]]W#S'GW^HW^-
MKIGX.L2:H@M)9A$5,;+1)(ZG;==]?'QTPA$36O)9#*-KA\C(1;:=FCY7%)L+
MZ +'%"6O-@J\(+"]$[OA#;RC=N"W&R>.W_!;7M#\S?/:GK=AX.^56VCCU4;'
MCN?X3O.HN2%XC\E7/*:H=[$AV#@F1Z2)6SX];1TU\?"4! U" G]T[&%_2,DF
M4CE=*C:>Q.@=>9] !'^%H)S3);IB @O",$</J:>_HYX@#NIRCOI&3:,^U53-
M:>@\6>7 6YNGY,$<"9W\[%@;["V&BCM2C=W \QIN*FT]B2]VY!\;B;3?:K7<
MY.I:5+,\03#KNY]OKA_(A$;8AJF"*"!F ,W:.OGS6I)DCO; A0HES"\[%;/-
M7[8?V W?6>C0 C806O&A)*=].D+F\Z]^;VO,"552Q(LDALP$>"=!TS6"[H!&
M4PX1=+UR.+$T470$ZBI>V*FP&>S7/-EX.86@UPRN@.ON:_#$>"&%C)8K8.DM
MD7YV17@I8A8O>V(D593P^A+@/ACZ<HBA8F^F"F)0Q(FT\7]+@2YB*D(:IF:,
M Y7XFP!*(7%)MOV'\30,F(2/IL09R[D;4I:,:+XDY"3$P(\O#Y3,%-B_7) )
M%F-ZBR.ZS0,WX2M5^B?'0\H[5K&N6R:\@<(FS3XLHZ'D^^)ZIE0JH-1G/Q@.
M6,P/YBK3*Q76O:+G,H*((=2$34_K&54#$X[J;C2B:E^8+]NI$O;K 5<'%18F
M1E@,<74#R4_!6K7WU.=HE@KM'P@L2#V&AYE@J\5&[XNN0+E4@&8%Y/<3J(QN
M9]%P_\G=U2L5UCG<CUTHH,YEN/=]O*U3*IQ5HN^&(2PR^EY"(<'_9=-#P'W+
M0G50'V ]I'?J7LDY6Y4^AX/=L5$=7#.#=VH@'\5W(=U4KP[DTP?4&#3X+IC;
M!GX(4/^U0/U*@ [PHA?"TL!&3]GML!ST@I$* $/?(]54JF2<Y,8XES,1J^7A
MJ> %4Q6 OV+\P"2_JU<!K,N(JC&LP)^4?(PGL-A-L5@>AK# 1 5@SR'0%.8]
M*&46?](#8>XH5P"P3\=,PR@B/J1=R-<M%5[:-MU#F26A<PK-MLB^^ J42P78
MA0%",\@5Q^-]@3U3JH2Q 6 XE*B53KDEF9Q3U1V: "'QWC79MM(VH,V6O:O(
MEDFL2&H.ON[TZ]L[,$\2[A0KL&>3">/K5G^D9)2+Y6DTF4><5-"J="S?\WS/
M\3P+32'N3(_8L6#)GFD (Z<&MFD8P WH:10-KU=^%\),,$*;H6DB^7^FXUE<
M9WP<UY./@@24\=(JFQ< ,Y1O@)G\I6--C-^H9\ 4K/@9+\TZ\U)0L*W9"6J:
M=G<+[HR2FF;>O;JEC*72\_!;8JFP%5[STZAU.L[=U\BXJ75*SMV<6G-S5.N$
MG+._F#%3Z[Q<M$><T5/SPCA_QW]-SW'I^?BMT+/]M"8CI*9)>/=YVIJ2DYKF
MWH+'GQDO-<V\>0^M,U)J6@!_Z[#!FIQF3:O?EX^.9!35-/_N'@):4W):T_S[
M[*Q6QD==\V[NF;J,EA^0><_<'5:@4_MJCMRNKI@W<PSUPW]02P,$%     @
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MS/:DIF?!>P0NKW][)1.N>"F_9DR8V:WWS(77@T?RH#QOEM+,U\D+7VPQ%=5
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MA#3':^;=CD:VL T> ?"<O4YN-^')W?N<YN7> KDH*,0@2WD%3P8@\U'!4N,
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M4$L! A0#%     @ !T7>5/$Z9$LB$@  )HX  !0              ( !BA$
M &AR='@M.&M?,C R,C V,C<N:'1M4$L! A0#%     @ !T7>5!BC9I:+%0
MV&P  !               ( !WB,  &AR='@M97@Y.3%?-BYH=&U02P4&
/  4 !0!% 0  ESD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
